A Regenerative Medicine Company
Longeveron was founded to provide stem cell therapeutics for unmet medical needs. The company’s lead product, Longeveron Mesenchymal Stem Cells (LMSCs), is currently being evaluated in several Phase 1 – 2b clinical trials under FDA oversight. Indications being explored include Aging Frailty, hypoplastic left heart syndrome, the metabolic syndrome, and Alzheimer’s disease. Longeveron is a private company, and recipient of 5 grant awards, including from the National Institutes of Health (National Institute of Aging), the Alzheimer’s Association, and the Maryland Stem Cell Research Fund (MSCRF)/TECDO.